Indoor Cultivation Facility in Macedonia Will Use Swedish LED Grow Light Technology to Accelerate Harvest and Deliver Medicinal-Grade Cannabis
Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces an order from Medical 420 a medicinal cannabis cultivation facility in Macedonia. The indoor controlled environment facility is investing in Heliospectra LED lighting solutions to improve quality, accelerate harvest cycles and increase yields. The order is valued at $117,000 USD (984,000 SEK).
“We are committed to growing the highest-grade flower and distilling the highest-grade concentrates in order to deliver consistent medical products and treatments to patients. Heliospectra has proven that they offer a robust solution with market-leading light quality and uniform distribution. This allows us to standardize highest quality while increasing yields,” said Tony Gasovski, owner and founder of Medical 420.
The Republic of Macedonia legalized the use of cannabis for medical purposes in 2016, following European countries such as the Netherlands, Czech Republic and Portugal. Unlike most EU countries, production will not be carried out by a state monopoly, which has opened up the market as a potential production base for numerous companies, both local and international.
Medical 420 is setting up a brand new vertical cultivation facility in Macedonia, and has chosen Heliospectra’s intense E60 series as sole-source lighting. The E60 is a fixed spectrum, high intensity LED grow light fixture developed together with some of the world’s leading commercial growers. The lamp has an optimized spectrum and its plug-and-play nature provides instant, high-quality light for horticulture crop production year round.
“Heliospectra’s proven solutions deliver superior performance and durability while also achieving business advantages for growers and producers in the global marketplace. The ability to accelerate harvest while increasing yields and improving the quality of crops provides growers like Medical 420 with reliable, repeatable production forecasts and the opportunity to negotiate premium placement in the marketplace,” said Ali Ahmadian, Heliospectra, CEO.
Delivery will take place and will be visible in the accounts in Q4.
Heliospectra Investor Relations:
Ali Ahmadian, CEO of Heliospectra | +46 (0)72 203 6344 |
Redeye is Heliospectra Certified Advisor for Nasdaq First North - www.redeye.se
Heliospectra AB (publ) (OTCQB: HLS, FIRST NORTH: HELIO) is the industry’s most proven intelligent lighting technology for greenhouse and controlled plant growth environments. With the vision to make commercial crop production more connected and resource-efficient, growers and commercial producers across six continents use Heliospectra’s holistic and flexible solutions to consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Founded in 2006 and winner of multiple international awards and recognitions, Heliospectra has raised more than $32 million in capital to date. As a publicly traded company, the majority ownership remains with some of Heliospectra earliest investors Weland Steel, Midroc New Technology and Swedish Industrial Fund. For more information, please visit https://www.heliospectra.com.
The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.
This information is information that Heliospectra AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET / 6 AM EST on October 31, 2017.